Pfizer Corporation

David Hepworth

Joseph Walter Strohbach

Stephen Wayne Wright

Frank Eldridge Lovering

Christoph Martin Dehnhardt

Eddine Saiah

Christoph Wolfgang Zapf

Arthur Lee

Nikolaos Papaioannou

Katherine Lin Lee

John David Trzupek

Seungil Han

Lori Krim Gavrin

John Paul Mathias

Akshay Patny

Kevin Joseph Curran

Xiaolun Wang

Joel A Goldberg

Michael Dennis Lowe

Richard Vargas

Robert L Dow

David R Anderson

Mark Edward Bunnage

Horng-Chih Huang

Donald Stuart Middleton

Mark David Andrews

Betsy Susan Pierce

Shawn Cabral

Roger B Ruggeri

Alan Stobie

Chulho Choi

Andrew Douglas Baxter

Philip Albert Carpino

David W Piotrowski

Ariamala Gopalsamy

Agustin Casimiro-Garcia

Charlotte Moira Norfor Allerton

Daniel Wei-Shung Kung

Ralph Pelton Robinson, Jr

Mihir D Parikh

Andrew Simon Cook

Edward L Conn

Arjun Venkat Narayanan

Hatice Gizem Yayla

Christophe Philippe Allais

Jayasankar Jasti

Ming Zhu Chen

Olugbeminiyi Omezia Fadeyi

Suvi Orr

Stephen Kwok-Fung Wong

Kentaro Futatsugi

Matthew Scott Dowling

Dafydd Rhys Owen

Lee Richard Roberts

Joseph Scott Warmus

Geoffrey E Gymer

Lyn Howard Jones

Matthew Forrest Sammons

Mavis Diane Adam

Benjamin N Rocke

Yan Zhang

Harry Ralph Howard

Andrew Simon Bell

Christopher Ronald Smith

Harry R Howard, Jr

Kim Huard

David Ellis

Suvi Tuula Marjukka Orr

Andrew Antony Calabrese

Daniel W Kung

Duncan Robert Armour

Markus Boehm

Mark Leonard Elliott

Mark Ian Lansdell

Paul John Edwards

Mark Llewellyn Lewis

Jian Wang

David Sebastien Fradet

Agustin Casimiro Garcia

Kun Song

Kay Ahn

David Randolph Anderson

Joel Adam Goldberg

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

Chemical compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, Rand Rare as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. 

Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme

Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. 

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

2-thiopyrimidinones

Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Diacylglycerol acyltransferase 2 inhibitors

Growing community of inventors

Concord, MA, United States of America

David Hepworth